Definitive Healthcare (DH) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $61.5 million, down 1% year-over-year, but above the high end of guidance [3][21] - Adjusted EBITDA was $18.1 million, representing a margin of 29%, which was $1.1 million above the high end of guidance [3][4] - Adjusted net income was $8.6 million, resulting in $0.06 of non-GAAP earnings per share [21] - Unlevered Free Cash Flow for the trailing 12 months was approximately $55 million [4] Business Line Data and Key Metrics Changes - Subscription revenues were $58.5 million, down 3% year-over-year, or down 7% excluding data partnership contributions [22] - Professional services revenue increased by 49% year-over-year, driven by traditional analytics engagements and ramp-up in digital activations [22] - Adjusted gross profit was $50.2 million, flat from Q4 2024, with an adjusted gross profit margin of 82%, expanding about 100 basis points year-over-year [23] Market Data and Key Metrics Changes - Gross dollar retention improved by about 2 points year-over-year, reflecting initial impacts of actions taken to stabilize the business [24] - Net dollar retention declined due to ongoing pressure in upsell opportunities [24] Company Strategy and Development Direction - The company focuses on four strategic pillars: data differentiation, integrations, customer success, and innovation [4][19] - Plans to invest in areas showing promise, particularly digital activation and partnerships, while maintaining strong margins [19][32] - The company aims to return to consistent revenue growth, with a focus on improving retention [19][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the remediation of claims data disruption and its positive impact on performance moving into 2026 [36][44] - The macro environment remains challenging, but the company will focus on controllable areas and necessary investments to improve operational performance [19][32] - Management expects to see improvements in net dollar retention in 2026, viewing 2025 as the bottom [55][78] Other Important Information - The company capitalized about $6 million in software development spend, a $5 million increase over the prior year [26] - Deferred revenue was $99 million, up 6% year-over-year, while total remaining performance obligations declined 18% year-over-year [27] Q&A Session Summary Question: Update on demand environment across end markets - Management noted improvements in retention trends and confidence in the strategy focused on data quality and integrations [36][37] Question: Insights on renewal cycles across end markets - Management highlighted improvements in gross dollar retention driven by enterprise customers, particularly in life sciences [42][43] Question: Impact of AI on customer conversations - Management emphasized that AI is seen as a competitive advantage, enhancing existing workflows and use cases [51][53] Question: Expectations for net dollar retention improvement - Management expects modest improvement in net dollar retention in 2026, with confidence in product innovation and data remediation efforts [55][78] Question: Dynamics in the life sciences end market - Management reported stabilization in gross dollar retention and ongoing engagement with long-standing relationships in the life sciences space [84][85] Question: Return on organic innovation spend - Management indicated that product releases are expected to ramp up in Q2, with ongoing focus on AI-enabled product development [87]